Shaghaghi Zahra, Hosseinimehr Seyed Jalal
Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Recent Pat Anticancer Drug Discov. 2017 Nov 20;12(4):323-339. doi: 10.2174/1574892812666170829150057.
Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
表皮生长因子受体(EGFR)在多种癌症中过度表达,与预后不良、低生存率以及癌细胞对治疗的耐药性相关。
本综述探讨EGFR抑制剂与放射治疗联合在癌症治疗中的效果。
考虑了近期的文献和专利申请,其中EGFR在癌症中的作用、EGFR抑制剂以及临床前和临床研究均与EGFR抑制剂和电离辐射在治疗各种癌症中的协同作用相关。
特异性抑制已作为癌症治疗的靶向疗法引入。抑制EGFR的两种主要药理学方法是单克隆抗体和小分子酪氨酸激酶抑制剂。这些药物与电离辐射联合使用可增加对富含EGFR表达的肿瘤的细胞毒性。
EGFR抑制剂与电离辐射联合具有协同作用,可改善患者的放射治疗效果。